title: Identification of a potential human telomerase reverse transcriptase-derived, HLA-A1-restricted cytotoxic T-lymphocyte epitope.
abstract: The catalytic subunit of human telomerase reverse transcriptase (hTERT) is expressed in the majority of tumor cells of different histological origins as opposed to most normal somatic cells. This implicates hTERT as a widely expressed tumor-associated antigen and an attractive candidate for antigen-specific tumor immunotherapy. T lymphocytes specific for hTERT-derived epitopes have been isolated and shown reactive with hTERT-expressing tumor cells. To further increase the applicability of hTERT as a target antigen for immunotherapy, we set out to identify potential hTERT-derived, HLA-A1-restricted cytotoxic T-lymphocyte (CTL) epitopes. The "reverse immunology" approach, involving computer-assisted epitope prediction, in vitro CTL induction, and tetramer-guided CTL isolation, resulted in specific CTLs against hTERT-derived, HLA-A1-binding peptides. Intermediate- to low-avidity CTLs were induced against the hTERT325-333 peptide and recognized endogenously processed hTERT. Recognition of endogenous hTERT depended on an increase of hTERT expression above normal levels in tumor cells through hTERT transduction, most probably as a result of limited CTL avidity. The altered peptide ligand hTERT699T-707 was designed to increase HLA-A1-binding affinity of the hTERT699-707 peptide and was used to induce CTLs. However, these CTLs poorly cross-recognized native hTERT699-707 and failed to recognize endogenously processed hTERT. In conclusion, our study has identified the hTERT325-333 peptide as a potential hTERT-derived epitope that may prove useful for induction and monitoring of hTERT-specific, HLA-A1-restricted CTL responses.
authors.affiliation: Department of Pathology, VU University Medical Center, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
authors.forename: Marco W J
authors.initials: MW
authors.lastname: Schreurs
authors.forename: Esther W M
authors.initials: EW
authors.lastname: Kueter
authors.forename: Kirsten B J
authors.initials: KB
authors.lastname: Scholten
authors.forename: Duco
authors.initials: D
authors.lastname: Kramer
authors.forename: Chris J L M
authors.initials: CJ
authors.lastname: Meijer
authors.forename: Erik
authors.initials: E
authors.lastname: Hooijberg
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology*; D004268:DNA-Binding Proteins; D000939:Epitopes / Q000737:chemistry / Q000276:immunology; D015788:HLA-A1 Antigen / Q000276:immunology*; D006801:Humans; D008545:Melanoma / Q000276:immunology*; D010446:Peptide Fragments; D012878:Skin Neoplasms / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D019098:Telomerase / Q000737:chemistry / Q000276:immunology*; D014407:Tumor Cells, Cultured
chemical_list: D000951:Antigens, Neoplasm; D004268:DNA-Binding Proteins; D000939:Epitopes; D015788:HLA-A1 Antigen; D010446:Peptide Fragments; D019098:Telomerase
references.citation: Blood. 2001 May 1;97(9):2903-7
references.pmid: 11313288
references.citation: Cancer Gene Ther. 2003 Mar;10(3):239-49
references.pmid: 12637945
references.citation: Immunogenetics. 1994;40(3):238-41
references.pmid: 8039832
references.citation: Nat Med. 2000 Sep;6(9):1011-7
references.pmid: 10973321
references.citation: J Immunol. 2002 Jun 1;168(11):5900-6
references.pmid: 12023395
references.citation: Cancer Immun. 2002 Oct 14;2:14
references.pmid: 12747759
references.citation: Immunogenetics. 1999 Nov;50(3-4):213-9
references.pmid: 10602881
references.citation: J Clin Invest. 2004 Feb;113(3):425-33
references.pmid: 14755339
references.citation: Oncogene. 2002 Jan 21;21(4):541-52
references.pmid: 11850779
references.citation: Eur J Immunol. 2001 Sep;31(9):2642-51
references.pmid: 11536162
references.citation: Oncogene. 2002 Jan 21;21(4):674-9
references.pmid: 11850795
references.citation: J Immunol. 2000 Oct 15;165(8):4239-45
references.pmid: 11035057
references.citation: Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4102-7
references.pmid: 8633023
references.citation: Cell Immunol. 1999 Jul 10;195(1):10-7
references.pmid: 10433792
references.citation: Int J Cancer. 2004 Feb 10;108(4):571-9
references.pmid: 14696122
references.citation: Hum Immunol. 2003 Feb;64(2):245-55
references.pmid: 12559627
references.citation: J Immunol. 1994 Apr 15;152(8):3913-24
references.pmid: 8144960
references.citation: Cancer Res. 2003 May 1;63(9):2127-33
references.pmid: 12727829
references.citation: Science. 1994 Dec 23;266(5193):2011-5
references.pmid: 7605428
references.citation: Int Rev Immunol. 2003 Mar-Apr;22(2):81-112
references.pmid: 12962271
references.citation: J Immunol. 1998 Dec 15;161(12):6956-62
references.pmid: 9862730
references.citation: J Immunol Methods. 1996 Sep 27;196(2):137-51
references.pmid: 8841452
references.citation: Clin Cancer Res. 2004 Jul 15;10(14):4688-98
references.pmid: 15269141
references.citation: Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14578-83
references.pmid: 11121060
references.citation: Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12275-80
references.pmid: 12218171
references.citation: Clin Cancer Res. 2003 Oct 15;9(13):4743-55
references.pmid: 14581345
references.citation: Clin Cancer Res. 2001 Nov;7(11):3343-8
references.pmid: 11705846
references.citation: J Immunother. 2002 Sep-Oct;25(5):429-38
references.pmid: 12218781
references.citation: Clin Cancer Res. 2004 Feb 1;10(3):828-39
references.pmid: 14871958
references.citation: Immunity. 1999 Jun;10(6):673-9
references.pmid: 10403642
references.citation: Hum Genet. 1986 Aug;73(4):320-6
references.pmid: 3017841
references.citation: J Immunol. 2003 Sep 15;171(6):2912-21
references.pmid: 12960314
references.citation: Immunol Today. 1999 Apr;20(4):177-80
references.pmid: 10203715
references.citation: Trends Cell Biol. 2003 Jun;13(6):289-94
references.pmid: 12791294
references.citation: Nat Immunol. 2001 Aug;2(8):711-7
references.pmid: 11477407
references.citation: J Immunol Methods. 1984 Aug 3;72(1):219-27
references.pmid: 6086760
references.citation: Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4796-801
references.pmid: 10759561
references.citation: J Immunol. 2000 Dec 1;165(11):6644-52
references.pmid: 11086110